Net revenue growth of 22% in Canada medical cannabis, 10% in Canada adult-use cannabis, 10% in international markets cannabis and 6% in Storz & Bickel
Adjusted gross margin(1) improves to 31% in Q1 FY2027 from 25% in Q1 FY2026
Adjusted EBITDA(2) loss narrows by 59% year-over-year
SMITHS FALLS, Ontario--(BUSINESS WIRE)--August 07, 2026--
Canopy Growth Corporation ("Canopy Growth", "our", "we" or the "Company") (TSX: WEED) (Nasdaq: CGC), a leading global company committed to bettering lives through cannabis, today announced its financial results for the three months ended June 30, 2026 ("Q1 FY2027"). All financial information in this press release is reported in Canadian dollars, unless otherwise indicated.
"The renewed focus and strong momentum we established over the past year have continued into fiscal 2027. In the first quarter, we achieved net revenue growth in every business through solid execution across the organization. We have clear strategies to deliver further growth in each of our end markets. At the heart of our cannabis strategy is our company-wide push to elevate cultivation and produce a consistent and increasing supply of high-quality flower that will support growing demand both in Canada and internationally."
Luc Mongeau, Chief Executive Officer
"The combination of top-line growth and disciplined cost management is enabling us to make steady progress on key profitability measures including gross margin and adjusted EBITDA. As expected, the integration of MTL Cannabis is leading to increased supply of high-quality flower, expanded revenue opportunities and the realization of meaningful synergies. We anticipate further improvements in our financial results, especially in the second half of fiscal 2027, as the integration is completed."
Tom Stewart, Chief Financial Officer
First Quarter FY2027 Financial Highlights
-- Consolidated net revenue of $81.2M in Q1 FY2027 increased by 13%
compared to the three months ended June 30, 2025 ("Q1 FY2026").
-- Cannabis net revenue was $65.1M in Q1 FY2027, an increase of 14%
versus the prior-year period.
-- Canada medical cannabis net revenue in Q1 FY2027 was
$25.8M, an increase of 22% versus Q1 FY2026, driven by
growth in the number of insured customers and the
acquisition of MTL Cannabis Corp. ("MTL Cannabis"),
partially offset by the Canadian government's reduction in
the Veterans Affairs Canada ("VAC") reimbursement rate for
medical cannabis.
-- Canada adult-use cannabis net revenue in Q1 FY2027 was
$29.7M, an increase of 10% compared to Q1 FY2026, primarily
attributable to increased flower sales driven by the
acquisition of MTL Cannabis, partially offset by declines
in opportunistic bulk sales.
-- International markets cannabis net revenue of $9.6M in Q1
FY2027 increased 10% over Q1 FY2026, primarily due to
strength in Europe, specifically in Poland.
-- Storz & Bickel net revenue was $16.1M in Q1 FY2027, a 6%
increase compared to Q1 FY2026. The growth is attributable to
prior-year product portfolio expansion and increasing sales across
non-core markets.
-- Consolidated gross margin was 27% in Q1 FY2027, compared to 25% in Q1
FY2026.
-- Adjusted gross margin1 increased to 31% in Q1 FY2027, as
compared to 25% in Q1 FY2026. The current year period excludes the
impact of inventory step-up charges ($2.6 million) related to the
acquisition of MTL Cannabis, which were not present in the
prior-year period.
-- Cannabis gross margin was 22% in Q1 FY2027 compared to 24% in Q1
FY2026, while adjusted gross margin1 for the segment was 26% in Q1
FY2027 compared to 24% in Q1 FY2026. The increase in the adjusted
gross margin percentage1 is primarily attributable to higher sales
across the cannabis segment, partially offset by the reduction in
the VAC reimbursement rate available for medical cannabis.
-- Storz & Bickel gross margin was 48% in Q1 FY2027 compared to 29%
in Q1 FY2026. The increase in gross margin is due to a cost
rationalization exercise implemented at the end of fiscal 2026, as
well as a recovery of certain U.S. tariffs in the period.
-- Selling, general and administrative expenses in Q1 FY2027 were 6%
higher than in Q1 FY2026. The increase was driven by the addition of the
MTL Cannabis operations, offset by lower costs resulting from continued
reductions in headcount and other cost reduction initiatives.
-- Net loss in Q1 FY2027 was 68% lower compared to Q1 FY2026.
-- Adjusted EBITDA2 loss for Q1 FY2027 was $3.2M, an improvement of $4.7M
or 59% compared to Q1 FY2026, primarily attributable to revenue growth
across both segments and continued cost savings, partially offset by the
reduction in the VAC reimbursement rate available for medical cannabis.
-- Free cash outflow3 increased from $11.6M in Q1 FY2026 to $25.7M in Q1
FY2027, reflecting increased cash used in operating activities, primarily
due to the timing of changes in working capital items.
Business Highlights
-- Canopy Growth's Apollo Cannabis Clinics were named Best Medical
Cannabis Clinic in the 2025 Toronto Star Readers' Choice Awards, an
indicator of the Company's commitment to positive patient outcomes.
-- Spectrum Therapeutics introduced new 30 and 90-pack formats for its
softgels with enhanced dosing options, offering greater value to medical
cannabis customers while reducing packaging and shipping costs.
-- The Company relaunched the Tweed brand in the German medical cannabis
market, taking advantage of MTL Cannabis' premium genetics and flower
production capacity to strengthen its international position.
-- Canopy Growth improved its adult-use market ranking to #6 overall in
Canada4, with top 2 positions in premium flower, infused pre-rolls, and
oils & softgels.
-- The Company expanded Claybourne's Frosted Flyers infused pre-roll
lineup in Canada, with three new 8-pack variety formats and the brand's
first bundle pack.
Canopy Growth Unveils Refreshed Corporate Identity
Canopy Growth unveiled a refreshed corporate identity designed to reflect our evolution into a modern cannabis company.
The new brand is built on our belief that cannabis has the power to better lives -- for patients seeking relief and balance, and for adult-use cannabis consumers looking for trusted, consistent experiences.
The new identity supports a clearer expression of our long-term strategy: building a focused, consumer-centric cannabis company grounded in quality, innovation, and disciplined execution. At the heart of the refreshed identity is the new brandmark featuring a canopy arch and cannabis plant, representing our presence across medical, wellness, and adult-use cannabis markets, and the cultivation at the root of everything we build.
The refreshed brand is live today across Canopy Growth's website and social channels. To see more, visit www.canopygrowth.com.
____________________ (1) Adjusted gross margin and adjusted gross margin percentage are non-GAAP measures. See "Non-GAAP Measures" and Schedules 5 and 6 for a reconciliation of adjusted gross margin on a consolidated basis and by segment. (2) Adjusted EBITDA is a non-GAAP measure. See "Non-GAAP Measures" and Schedule 7 for a reconciliation of net loss from continuing operations to adjusted EBITDA. (3) Free cash flow is a non-GAAP measure. See "Non-GAAP Measures" and Schedule 8 for a reconciliation of free cash flow - continuing operations. (4) Internal Market Model (Stativa), 13-week period ended June 28, 2026.
Webcast and Conference Call Information
The Company will host a conference call and audio webcast with Luc Mongeau, CEO and Tom Stewart, CFO at 10:00 AM Eastern Time on August 7, 2026.
Webcast Information
A live audio webcast will be available at:
https://onlinexperiences.com/Launch/QReg/ShowUUID=567345EB-EB0A-41BF-ABD6-785F173BBEFE
Replay Information
A replay will be accessible by webcast until 11:59 PM ET on November 5, 2026 at the same URL.
Non-GAAP Measures
Adjusted EBITDA is a non-GAAP measure used by management that is not defined by U.S. GAAP and may not be comparable to similar measures presented by other companies. Management believes Adjusted EBITDA is a useful measure for investors because it provides meaningful and useful financial information, as this measure demonstrates the operating performance of businesses. Adjusted EBITDA is calculated as the reported net income (loss), adjusted to exclude income tax recovery (expense); other income (expense), net; loss on equity method investments; share-based compensation expense; depreciation and amortization expense; asset impairment and restructuring costs; acquisition-related restructuring and other inventory write-downs; and charges related to the flow-through of inventory step-up on business combinations, and further adjusted to remove acquisition, divestiture, and other costs. Asset impairments related to periodic changes to the Company's supply chain processes are not excluded from Adjusted EBITDA given their occurrence through the normal course of core operational activities. Accordingly, management believes that Adjusted EBITDA provides meaningful and useful financial information as this measure demonstrates the operating performance of businesses. The Adjusted EBITDA reconciliation is presented within this
press release and explained in the Company's Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2026 (the "Form 10-Q") filed with the Securities and Exchange Commission ("SEC").
Free cash flow is a non-GAAP measure used by management that is not defined by U.S. GAAP and may not be comparable to similar measures presented by other companies. Management believes that free cash flow presents meaningful information regarding the amount of cash flow required to maintain and organically expand the Company's business, and that the free cash flow measure provides meaningful information regarding the Company's liquidity requirements. This measure is calculated as net cash provided by (used in) operating activities less purchases of and deposits on property, plant and equipment. The free cash flow reconciliation is presented within this press release and explained in the Form 10-Q.
Adjusted gross margin and adjusted gross margin percentage are non-GAAP measures used by management that are not defined by U.S. GAAP and may not be comparable to similar measures presented by other companies. Management believes that adjusted gross margin and adjusted gross margin percentage present meaningful and useful financial information as these measures provide insights into the gross margin performance of the business. Adjusted gross margin is calculated as gross margin excluding acquisition related restructuring and other inventory write-downs, and charges related to the flow-through of inventory step-up on business combinations. Adjusted gross margin percentage is calculated as adjusted gross margin divided by net revenue. The adjusted gross margin and adjusted gross margin percentage reconciliation is presented within this news release.
About Canopy Growth
Canopy Growth is a leading global company committed to bettering lives through cannabis. With a focus on cultivation excellence, quality, trust, innovation and disciplined execution, Canopy Growth is a consumer-centric company serving patients, consumers and partners alike.
The Company's portfolio of owned and licensed brands, including Tweed, 7ACRES, DOJA, Deep Space, DeeLish, Claybourne, MTL Cannabis, Low Key by MTL and R'belle, as well as category-defining Storz & Bickel, delivers innovative cannabis products to consumers across Canada and beyond. It is also Canada's leading provider of medical cannabis services through Spectrum Therapeutics, Abba Medix, Apollo and Canada House Clinics.
The Company also holds an unconsolidated, non-controlling interest in Canopy USA, LLC, which provides exposure to the U.S. THC market.
Guided by its commitment to leadership, excellence, trust and innovation, Canopy Growth is working to shape a future where the plant is trusted for its ability to better lives.
For more information visit www.canopygrowth.com.
Notice Regarding Forward Looking Statements
This press release contains "forward-looking statements" within the meaning of applicable securities laws, which involve certain known and unknown risks and uncertainties. To the extent any forward-looking statements in this press release constitutes "financial outlooks" within the meaning of applicable Canadian securities laws, the reader is cautioned that this information may not be appropriate for any other purpose and the reader should not place undue reliance on such financial outlooks. Forward-looking statements predict or describe our future operations, business plans, business and investment strategies and the performance of our investments. These forward-looking statements are generally identified by their use of such terms and phrases as "intend," "goal," "strategy," "estimate," "expect," "project," "projections," "forecasts," "plans," "seeks," "anticipates," "potential," "proposed," "will," "should," "could," "would," "may," "likely," "designed to," "foreseeable future," "believe," "scheduled" and other similar expressions. Our actual results or outcomes may differ materially from those anticipated. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date the statement was made.
Forward-looking statements include, but are not limited to, statements with respect to:
-- laws and regulations and any amendments thereto applicable to our
business and the impact thereof, including uncertainty regarding the
application of U.S. state and federal law to cannabis and hemp (including
hemp derived cannabidiol ("CBD")) products and the scope of any
regulations by the U.S. Food and Drug Administration, the U.S. Drug
Enforcement Administration, the U.S. Federal Trade Commission, the U.S.
Patent and Trademark Office, the U.S. Department of Agriculture and any
state equivalent regulatory agencies over cannabis and hemp (including
CBD) products;
-- expectations regarding the amount or frequency of impairment losses,
including as a result of the write-down of intangible assets, including
goodwill;
-- our ability to refinance debt as and when required on terms favorable
to us and comply with covenants contained in our debt facilities and debt
instruments;
-- the impacts of the Company's strategy to accelerate entry into the U.S.
cannabis market through the creation of Canopy USA, LLC ("Canopy USA");
-- expectations for Canopy USA to capitalize on the opportunity for growth
in the United States cannabis sector and the anticipated benefits of such
strategy;
-- the timing and occurrence of the final tranche closing in connection
with the acquisition of Lemurian, Inc. ("Jetty") by Canopy USA pursuant
to the exercise of the options to acquire Jetty;
-- the issuance of additional common shares of the Company (each whole
share, a "Canopy Share" or a "Share") to satisfy any deferred and/or
option exercise payments to the shareholders of Wana Wellness, LLC, The
Cima Group, LLC, and Mountain High Products, LLC (collectively, "Wana")
and Jetty and the issuance of additional non-voting and non-participating
shares in the capital of Canopy USA issuable to Canopy Growth from Canopy
USA in consideration thereof;
-- the acquisition of additional Class A shares of Canopy USA in
connection with the investment in Canopy USA by the Huneeus 2017
Irrevocable Trust (the "Trust") in the aggregate amount of up to US$20
million, including any warrants of Canopy USA issued to the Trust in
accordance with the share purchase agreement entered into by the Trust
and Canopy USA;
-- expectations regarding the potential success of, and the costs and
benefits associated with, our acquisitions, equity investments and
dispositions, including our acquisition of MTL Cannabis;
-- the grant, renewal and impact of any license or supplemental license to
conduct activities with cannabis or any amendments thereof;
-- our international activities, including required regulatory approvals
and licensing, anticipated costs and timing, and expected impact;
-- our ability to successfully create and launch brands and further create,
launch and scale products in jurisdictions where such products are legal
and that we currently operate in;
-- the benefits, viability, safety, efficacy, dosing and social acceptance
of cannabis, including CBD and other cannabinoids;
-- our remediation plan and our ability to remediate the material weakness
in our internal control over financial reporting;
-- expectations regarding the use of proceeds of equity financings;
-- the legalization of the use of cannabis for medical or adult-use in
jurisdictions outside of Canada, the related timing and impact thereof
and our intentions to participate in such markets, if and when such use
is legalized;
-- the impact of the implementation of the rescheduling of medical
cannabis from a Schedule I controlled substance under the United States
Controlled Substances Act (21 U.S.C. -- 811) to a Schedule III controlled
substance;
-- our ability to execute on our strategy and the anticipated benefits of
such strategy;
-- the ongoing impact of the legalization of additional cannabis product
types and forms for adult-use in Canada, including federal, provincial,
territorial and municipal regulations pertaining thereto, the related
timing and impact thereof and our intentions to participate in such
markets;
-- the ongoing impact of developing provincial, state, territorial and
municipal regulations pertaining to the sale and distribution of cannabis,
the related timing and impact thereof, as well as the restrictions on
federally regulated cannabis producers participating in certain retail
markets and our intentions to participate in such markets to the extent
permissible;
-- the timing and nature of legislative changes in the U.S. regarding the
regulation of cannabis including tetrahydrocannabinol;
-- the future performance of our business and operations;
-- our competitive advantages and business strategies;
-- the competitive conditions of the industry;
-- the expected growth in the number of customers using our products;
-- expectations regarding revenues, expenses and anticipated cash needs;
-- expectations regarding cash flow, liquidity and sources of funding;
-- expectations regarding capital expenditures;
-- the expansion of our production and manufacturing, the costs and timing
associated therewith and the receipt of applicable production and sale
licenses;
-- expectations with respect to our growing, production and supply chain
capacities;
-- expectations regarding the resolution of litigation and other legal and
Comments